Pioneering partnership advances
innovative health monitoring, setting the stage for future
enterprise opportunities.
PLEASANTON, Calif., June 10,
2024 /PRNewswire/ -- In a strategic move that could
reshape the understanding of long COVID and chronic Lyme disease,
the Massachusetts Institute of
Technology (MIT) has forged a
partnership with Movano Health for its MAESTRO study to harness the
medical grade continuous health monitoring capabilities of Movano's
Evie Ring.
The MAESTRO study, a comprehensive study using the latest
advancements in medical research, will recruit 300 adults aged
18-35 across four distinct cohorts: those with acute Lyme disease,
chronic Lyme disease, long COVID, and a control group. With an
estimated 40 million Americans grappling with the debilitating
effects of long COVID, and over 600,000 new cases per year of Lyme
disease, 10-15% of which will manifest as chronic Lyme, the
long-term health impacts of these conditions are still shrouded in
mystery. This study holds the promise of unlocking vital
answers.
"This collaboration signals a vote of confidence from one of the
world's preeminent research institutions in Movano's ability to
provide continuous, reliable, and convenient access to a large data
set, ushering in a new era of personalized patient care and
scientific discovery," said John
Mastrototaro, CEO of Movano Health. "Our ring solution,
designed to meet stringent HIPAA and cybersecurity standards,
offers an innovative alternative to existing health monitoring
devices – a game-changing solution that is long overdue."
"We're excited to incorporate the Evie Ring into our clinical
study to evaluate the progression of long COVID and chronic Lyme
disease and paint a fuller picture of why some people bounce back
from a mild infection while others go on to endure prolonged
suffering," said Dr Michal Caspi
Tal, Associate Scientific Director, the MIT Center for
Gynepathology Research and head of the Tal Research Group. "The
breadth of longitudinal information related to vital signs and
wellness provided by the ring will be instrumental in enhancing our
understanding of these debilitating conditions."
About the Tal Research Group
Under the visionary
leadership of Michal Caspi Tal, PhD,
the Tal Research Group is a state-of-the-art immune engineering lab
dedicated to bridging critical knowledge gaps in chronic illness
research. Utilizing advanced technologies, this interdisciplinary
team pioneers translational and clinically significant studies to
enhance understanding, diagnostics, and treatments for complex
chronic conditions. Specializing in chronic Lyme disease, acute
Lyme disease, long COVID, and ME/CFS (myalgic
encephalomyelitis/chronic fatigue syndrome), the group investigates
their pathologies and co-occurring conditions. Focused on
innovative predictive diagnostics, the Tal Research Group
accelerates the discovery of disease trajectories and biomarkers,
setting new standards in medical research and patient care.
About Movano Health
Founded in 2018, Movano
Inc. (Nasdaq: MOVE) dba Movano Health is developing a suite of
purpose-driven healthcare solutions to bring medical-grade data to
the forefront of wearables. Featuring modern and flexible form
factors, Movano Health's devices offer an innovative approach to
delivering trusted data to both customers and enterprises,
capturing a comprehensive picture of an individual's health data
and uniquely translating it into personalized and intelligent
insights.
Movano Health's proprietary technologies and wearable medical
device solutions will soon enable the use of continuous data as a
tool to proactively monitor and manage health outcomes across a
number of patient populations that exist in healthcare. For more
information on Movano Health, visit https://movanohealth.com/.
Forward Looking Statements
This press release contains
forward-looking statements concerning our expectations,
anticipations, intentions, beliefs, or strategies regarding the
future. These forward-looking statements are based on assumptions
that we have made as of the date hereof and are subject to known
and unknown risks and uncertainties that could cause actual
results, conditions, and events to differ materially from those
anticipated. Therefore, you should not place undue reliance on
forward-looking statements. Examples of forward-looking statements
include, among others, statements we make regarding plans with
respect to the commercial launches of the Evie Ring and Evie Med;
planned cost-cutting initiatives; anticipated FDA clearance
decisions with respect to our products; expected future operating
results; product development and features, product releases,
clinical trials and regulatory initiatives; our strategies,
positioning and expectations for future events or performance.
Important factors that could cause actual results to differ
materially from those in the forward-looking statements are set
forth in our most recent Annual Report on Form 10-K and any
subsequent Quarterly Reports on Form 10-Q, and in our other reports
filed with the Securities and Exchange Commission, including under
the caption "Risk Factors." Any forward-looking statement in
this release speaks only as of the date of this release. We
undertake no obligation to publicly update any forward-looking
statement, whether written or oral, that may be made from time to
time, whether as a result of new information, future developments
or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mit-selects-movano-health-for-groundbreaking-study-on-long-covid-and-chronic-lyme-disease-302167841.html
SOURCE Movano
